Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC WainwrightMarket Beat·Aug 19 at 10:24 AMDRUG-1.45%
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5.9% - Should You Buy?Market Beat·Aug 18 at 03:00 PMDRUG-1.45%JPM+0.01%
BTIG Research Reiterates "Buy" Rating for Bright Minds Biosciences (NASDAQ:DRUG)Market Beat·Aug 17 at 11:42 AMDRUG-1.45%RY+0.01%
ADAR1 Capital Management LLC Has $2.47 Million Stock Position in Bright Minds Biosciences Inc. $DRUGMarket Beat·Jul 29 at 02:04 AMDRUG-1.45%
We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn RateSimplywall·Jun 30 at 06:55 AMDRUG-1.45%
H.C. Wainwright Keeps Their Buy Rating on Bright Minds Biosciences (DRUG)Tip Ranks·Jun 25 at 03:45 PMDRUG-1.45%
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference | DRUG Stock NewsStockTitan·May 26 at 10:20 AMDRUG-1.45%BBH+1.74%
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipelinenasdaq·May 21 at 05:00 PMDRUG-1.45%FBT+1.05%
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical usebusinessinsider·Apr 20 at 01:02 PMCMPS-3.55%SILO-3.28%
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG ResearchMarket Beat·Mar 30 at 07:08 AMVHT+1.24%LABU+4.03%
Canadian Securities Exchange Reports January 2026 Performance FiguresNewsfile Corp.·Feb 17 at 09:09 AMDRUG-1.45%
